Can-Fite BioPharma Ltd. CANF 深 沪
已收盘 08-21 16:00:00 美东时间
3.33
-0.020
-0.60%
华盛通- 最 高3.48
- 今 开3.35
- 成交量 2.56万股
- 最 低 3.33
- 昨 收 3.35
- 总市值 713.47万
- 52周最高 13.40
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 2.56
- 委 比 93.24%
- 总股本 214.25万
- 历史最高 28380.00
- 量 比 0.65
- 振 幅 4.48%
- 历史最低 3.33
- 每 手 1
- 风险率 3.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite BioPharma Ltd. announced updates on its two lead drug candidates, Piclidenoson and Namodenoson, both advancing in Phase III clinical programs under FDA and EMA regulatory frameworks. Namodenoson, an orally administered A3AR agonist, is in a pivotal Phase III study for treating advanced liver cancer (HCC) with Child-Pugh B7 cirrhosis, supported by FDA Fast Track and Orphan Drug designations. Piclidenoson, targeting moderate-to-severe plaq...
08-12 11:00
Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeli...
08-03 19:03
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Can-Fite BioPharma Ltd. submitted a Phase 2 clinical study protocol for Piclidenoson to treat Lowe syndrome, a rare genetic disorder with no approved therapies. The study, led by Prof. Francesco Emma at Bambino Gesù Children's Hospital in Rome, will evaluate Piclidenoson's efficacy and safety in 5 adult patients over six months. The primary endpoint is improved renal function. This marks an important milestone for Can-Fite, aiming to support regu...
08-03 11:00
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite BioPharma announced that the Australian Patent Office has allowed a patent for "Treatment of Advanced Metastatic Cancer," strengthening its intellectual property around Namodenoson. Namodenoson, targeting A3 adenosine receptors, is in pivotal Phase 3 for hepatocellular carcinoma and Phase 2a for pancreatic cancer, showing promising safety and efficacy. The patent reinforces Can-Fite's oncology portfolio and extends protection in a major ...
07-14 11:00
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and in...
07-06 19:06
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Can-Fite BioPharma has completed enrollment of 247 patients in its pivotal Phase 3 study for Piclidenoson, a treatment for moderate-to-severe plaque psoriasis. The study has reached the pre-specified interim analysis stage under an FDA- and EMA-agreed protocol. Results are expected in Q4 2026/Q1 2027. Piclidenoson, an oral A3 adenosine receptor agonist, targets inflammatory pathways and has shown a favorable safety profile in over 1,500 subjects....
07-06 11:00
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case
Can-Fite BioPharma Ltd. (NYSE:CANF), a clinical-stage biotech, saw its shares jump on Friday after the company secured a Japanese patent allowance for its anti-obesity technology. The Japanese Patent Office allowed Patent Application No. 2025-049941, covering the use of A3 adenosine receptor agonist...
06-26 22:08
Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity
The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biot...
06-26 19:04
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite BioPharma Ltd. announced that the Japan Patent Office has allowed a patent for Namodenoson, its lead drug candidate, covering its use for fat loss and treating obesity and metabolic disorders. This milestone strengthens Can-Fite's global intellectual property portfolio, which already includes patent protections in major markets like the U.S., Canada, Australia, and Israel. The patent allowance underscores Namodenoson's potential as a dif...
06-26 11:00
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite BioPharma Ltd. will participate in the BIO International Convention 2026 to discuss licensing and commercialization opportunities for its clinical-stage pipeline, including Namodenoson for advanced hepatocellular carcinoma and Piclidenoson for inflammatory diseases. The company's A3AR platform has shown a favorable safety profile in over 1,600 patients and has generated $20 million in licensing agreements. Can-Fite aims to maximize globa...
06-17 11:00
